Is modulation of glucocerebrosidase a viable new treatment for Parkinson's disease? by Zurbruegg, Mark
DEPARTMENT OF CLINICAL NEUROSCIENCE 
Karolinska Institutet, Stockholm, Sweden 
IS MODULATION OF 
GLUCOCEREBROSIDASE A VIABLE NEW 
TREATMENT FOR PARKINSON'S DISEASE? 
Mark Zurbruegg 
 
Stockholm 2019 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Printed by Eprint AB 2019 
© Mark Zurbruegg, 2019 
ISBN 978-91-7831-580-2 
  
 
IS MODULATION OF GLUCOCEREBROSIDASE A 
VIABLE NEW TREATMENT FOR PARKINSON'S 
DISEASE?  
THESIS FOR LICENTIATE DEGREE 
By 
Mark Zurbruegg 
Principal Supervisor: 
Professor Per Svenningsson, 
Karolinska Institutet 
Department of Clinical Neuroscience 
 
Co-supervisor(s): 
Assistant professor Xiaoqun Zhang, 
Karolinska Institutet, 
Department of Clinical Neuroscience 
 
Lina Leinartaite, 
Karolinska Institutet, 
Department of Clinical Neuroscience 
 
Professor Karima Chergui, 
Karolinska Instituet, 
Department of Physiology and Pharmacology 
Examination Board: 
Professor Anna Erlandsson, 
Uppsala University, 
Department of Public Health and Caring Sciences, 
Geriatrics;  
 
Professor Lars Tjernberg, 
Karolinska Instituet, 
Department of Neurobiology 
 
Professor Henrietta Nielsen, 
Stockholm University, 
Department of neurochemistry and neurobiology 
 
 
  
 
 
Expression of gratitude 
Primarily I would like to thank Per Svenningsson for helping organize, fund and 
guide my research, as well as providing valuable input into shaping the project and 
encouraging comments about the work. Without him this thesis would not have been 
possible. I would also like to thank all members of the Svenningsson lab that have 
supported my research and helped me perform experiments. I would like to specially 
thank, Wojciech Paslawski who has been very helpful in teaching me various 
aspects of α-synuclein biochemistry. 
Personally, I would like to thank Margaret von Lerber my grandmother who 
developed Parkinson’s disease. Her kindness and compassion will always be 
remembered. 
 
 
  
1 ABSTRACT 
Background: Parkinson`s disease is the second most prevalent neurodegenerative 
disorder. There are currently no treatments that cure Parkinson’s disease (PD) or 
slow its progression. There is therefore an urgent need for novel treatments. It was 
recently discovered that patients with mutations in GBA1 are more likely to develop 
PD. GBA1 encodes the glucocerebrosidase protein (GCase). GCase is a lysosomal 
enzyme that breaks down glucosylceramide. Several studies suggest that a 
decrease in GCase activity and the accompanying increase in upstream 
glycosphingolipids cause an increase in levels of α-synuclein and its propensity for 
aggregation. We investigate if there is a molecular link between GCase activity and 
α-synuclein. Furthermore, we study the endogenous GCase activator saposin C. 
Saposin C is a sphingolipid activator protein that acts as a co-factor for 
glucosylceramide degradation by enabling GCase access to the lipid membrane. 
Aims: We aim to investigate how GBA1 mutations predispose to PD. Additionally we 
attempt to increase GCase activity using saposin C, and whether activation of 
GCase with saposin C is protective in PD. 
Methods and results: We studied the effect of GCase inhibition or genetic 
manipulation in SH-SY5Ycells. We establish that knockdown using RNA interference 
(RNAi) of GCase increases levels of α-synuclein. However, using a potent chemical 
inhibitor of GCase does not alter levels of α-synuclein. This finding suggests that 
GCase has an activity independent function that relies on the protein but not its 
enzymatic action to influence levels of α-synuclein. We are the first group to show 
that genetic and chemical inhibition produce different results. The increase in α-
synuclein can be returned to physiological levels by addition of active recombinant 
GCase. Our data suggests that using GCase chaperones to aid folding and 
trafficking could be protective in PD patients with GBA1 mutations. 
To assess whether saposin C has a protective role in PD we generated short peptide 
fragments of different regions of saposin C. We confirmed that the GCase activating 
sequence is encoded in amino acids 41-68. We synthesized a cell-permeable 
peptide but were unable to achieve increase in GCase activity. We therefore, 
created a cell line overexpressing full length prosaposin. We could show that this 
leads to a natural increase in GCase activity and decrease in levels of α-synuclein. 
We show that the decrease in α-synuclein is independent of GCase activity as it 
  
persists in CBE inhibited cells. We also provide preliminary evidence that saposin C 
can detach α-synuclein from artificial lipid membranes that act as a primary site for 
α-synuclein aggregation. Saposin C is therefore an interesting target for further 
studies.  
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2 INTRODUCTION 
2.1 PARKINSON’S DISEASE PREVALENCE 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder 
after Alzheimer’s disease.  The clinical hallmarks of Parkinson’s are bradykinesia, 
resting tremor, rigidity, and postural instability. It has an estimated prevalence of  1-
2% of the population aged 60 and above rising up to 3-4% at age 80 or above 
resulting in a 1.5% lifetime risk of developing PD (Bower, Maraganore, McDonnell, & 
Rocca, 1999; Nussbaum & Ellis, 2009; Tanner & Goldman, 1996). As prevalence of 
PD and other neurodegenerative diseases increases there is an equal increase in 
the care costs of these patients. Not only the cost of care has to be considered but 
also the great personal tragedy that unfolds in every single case of PD. It is 
important to remember that every statistic represents actual people that slowly 
become unable to live their normal lives, losing control of their own body. It is 
therefore not only an economic but also a moral imperative to further our 
understanding of this disease, with the eventual hope of a cure. 
2.2 HISTORY OF PD 
There are reports of Parkinson like illnesses dating back to 600 BC in the ancient 
Indian Ayurveda texts. The main pathological symptoms were identified as 
bradykinesia, rigidity of skeletal and facial muscles, resting tremor, as well as 
postural instability. Surprisingly the treatment developed in ancient India, as early as 
300 BC, were seeds from Mucuna pruriens which contain up to 6% levodopa 
(Ovallath & Deepa, 2013). Further descriptions of patients now thought to have 
suffered from PD were made by Galen in 175 AD (Lanska, 2009). The first 
description of PD in modern medicine was made by the eponymous James 
Parkinson. He reported on six patients. He described them to be afflicted with a 
shaking palsy that was distinct from other known illnesses. He described Shaking 
Palsy (Paralysis Agitans) as an “involuntary tremulous motion, with lessened 
muscular power, in parts not in action and even when supported; with a propensity to 
bend the trunk forwards, and to pass from a walking to a running pace: the senses 
and intellects being uninjured” (Parkinson, 1817). While he did not have sufficient 
means to study this disease fully himself, he encouraged others to do so. Charcot 
lauded Parkinson for his accurate description of the disease. It was Charcot who 
  
formally characterized the cardinal feature of PD and described all signs and 
symptoms, but he named it after Parkinson to acknowledge his astute observations 
(Lanska, 2009). While Parkinson described originally that the intellect remained 
unaffected it is now widely accepted that nonmotor symptoms such as cognitive 
decline, autonomic failure and psychiatric problems accompany PD (Corti, Lesage, & 
Brice, 2011). 
Clues to the etiology of PD arose early in the 20th Century when Blocq and 
Marinescu reported on a patient who had her left substantia nigra destroyed by a 
tuberculoma. She displayed hemiparetic parkinsonism (Lanska, 2009). The typical 
Lewy bodies found in the classical PD cases were described by Friedrich Lewy 
(Lewy, 1912). However, it was not until 1919, when Trétiakoff a physician working 
with PD patients, that Lewy bodies in the substantia nigra were linked to the 
pathogenesis of PD (Lanska, 2009). It took nearly 40 years to confirm the 
importance of Lewy body pathology and loss of striatonigral neurons in PD 
(Greenfield & Bosanquet, 1953). 
While the pathophysiological understanding of PD only progressed slowly various 
treatments were found to be effective based on empirical evidence. The first 
treatment consisted of anticholinergic alkaloids such as extracts from belladonna.  
Hyoscyamine was found to be modestly effective in treatment of PD by Charcot’s 
student. After world war II several drugs were synthesized to replace the most 
common PD therapy which was still treatment with belladonna, these consisted of 
centrally acting anticholinergic drugs as well as synthetic anti-histamines such as 
diphenhydramine (Foley, 2003).  
A real breakthrough in pharmacotherapy did not occur again until the mid-sixties. It 
was becoming clear that dopamine was playing an important role in the brain 
(Montagu, 1957). Analysis of catecholamine distribution revealed it being highly 
localized within the neostriatum (Bertler & Rosengren, 1959). Very astute 
observations by Carlsson and colleagues led to the hypothesis that dopamine 
depletion was the cause of PD. Supporting evidence included the fact that reserpine, 
a vesicular monoamine transport blocker, could induce PD. Treatment with the 
precursor DOPA led to reversal of reserpine induced PD (Carlsson, 2001). This 
effect was then confirmed in idiopathic and influenza induced PD patients, in which 
DOPA led to a remarkable decrease in bradykinesia (Birkmayer & Hornykiewicz, 
1962). It was shown that with a slowly increasing dose of L-dopa and a peripheral 
  
DOPA-decarboxylase inhibitor the side effects were quite small (George C Cotzias, 
Papavasiliou, & Gellene, 1969). Development of a long acting form of levodopa as 
well as catechol-O-methyltransferase inhibitors made this therapy even more viable 
(Lanska, 2009). 
One of the problems of L-dopa therapy is that as PD progresses there are marked 
decreases in neurons that are able to convert DOPA to dopamine, leading to 
reduced signaling efficacy in the basal ganglia. Remarkably, a loss of 70-80% of 
tyrosine hydroxylase positive neurons is required before motor symptoms appear. 
Indicating that the basal ganglia system is very robust and good at compensating for 
a decrease in dopamine (Bernheimer, Birkmayer, Hornykiewicz, Jellinger, & 
Seitelberger, 1973). Therefore, a direct way to stimulate dopamine receptors that 
does not necessitate DOPA to dopamine conversion was desirable. Apomorphine a 
morphine derivative was noted to be highly similar in structure to dopamine, and it 
was shown that it acts as a dopamine receptor agonist (Ernst, 1965). Treatment of 
patients with apomorphine leads to significant improvement reducing bradykinesia, 
rigidity and tremor. However, apomorphine was never used routinely in the clinic due 
to liver toxicity (G C Cotzias, Papavasiliou, Tolosa, Mendez, & Bell-Midura, 1976). 
Instead ergot derivatives such as bromocriptine and pergolide were found to have 
dopaminergic activity and were used in combination with L-dopa (Calne et al., 1978; 
Galea Debono, Donaldson, Marsden, & Parkes, 1975). While dopaminergic agonists 
are less effective at alleviating symptoms of PD than levodopa, they also induce 
fewer side effects such as dyskinesia. A common therapeutic protocol combines low 
dose L-dopa with a dopaminergic agonist (Ch. Wolters, Tissingh, Bergmans, & 
Kuiper, 1995). 
In addition to Pharmacotherapy surgical approaches were attempted. Lesion of 
corticospinal pathways reduced the tremor but also paralyzed patients. Approaches 
with more finesse such as stereotactic surgery, lesioning the thalamus and caudate 
nucleus, were shown to improve parkinsonian symptoms without impairing normal 
function. Lesioning of the thalamus became a fairly common treatment (Gildenberg, 
1998). However, use of L-dopa largely replaced the use of surgical approaches. As 
limitations of pharmacotherapy became clear, renewed interest in surgical 
approaches led to the realization that lesioning of the external Globus pallidus and 
sub-thalamic nucleus were effective at treating PD (Gildenberg, 1998). Furthermore, 
deep brain stimulation of the subthalamic nucleus was shown to decrease 
  
parkinsonian symptoms, with fewer side-effects than destructive ablation (Benabid, 
Pollak, Louveau, Henry, & de Rougemont, 1987; Lanska, 2009). 
There have been tremendous advances in understanding PD pathology and etiology 
since its first description nearly 2500 years ago. Despite these advances we have 
not yet found a cure. However, the pace of research has rapidly accelerated and 
with advances in molecular biology and stem cell therapy, hope remains that one 
day we can cure PD and reverse the damage it does. However, the by far best 
approach would be to prevent people from developing PD. To achieve this goal, we 
must understand what causes PD. 
2.3 PD PATHOLOGY 
2.3.1 α-synuclein 
PD was considered to be a sporadic disease with no genetic involvement until the 
late 20th century. This was due to the observation that external poisons such as 
MPTP could induce Parkinsonism, and that patients exposed to the 1918 influenza 
developed PD. Furthermore, twin studies did not reveal a genetic involvement 
(Lanska, 2009; Poskanzer & Schwab, 1963). However, in 1990 there was a report of 
a family with autosomal dominant transmission of PD (Golbe, Di Iorio, Bonavita, 
Miller, & Duvoisin, 1990). Linkage analysis and sequencing of the suspected region 
revealed a mutation in the α-synuclein gene (Polymeropoulos et al., 1997). α-
synuclein is a 140 amino acid long protein that accumulates in the pre-synaptic 
nerve terminal. α-synuclein is also an integral part of Lewy bodies seen in PD 
(Spillantini et al., 1997). It turns out α-synuclein also has an important role in 
Alzheimer’s disease constituting the non-amyloid β component of the AD plaques 
(Uéda et al., 1993). Patients with α-synuclein mutations typically have a late onset, 
low case of tremor and large Lewy body inclusions. Common α-synuclein mutations 
such as, A53T, A30P, and E46K, are autosomal dominant (Lashuel, Overk, Oueslati, 
& Masliah, 2013). Even sporadic PD patients have α-synuclein inclusions in Lewy 
bodies and Lewy neurites (Irizarry et al., 1998). While the importance of α-synuclein 
in PD is widely recognized, the molecular mechanisms by which these mutations 
mediate neurotoxicity are still not clear. A large number of studies point to 
importance of oligomerization and fibril formation. (Lashuel et al., 2013; Prusiner, 
2012; Volpicelli-Daley, Luk, & Lee, 2014). However, we do not understand the role of 
α-synuclein in the body making it difficult to pinpoint any specific mechanism. 
  
α-synuclein most likely performs an important physiological role as it is conserved 
across many vertebrate species (George, 2002). Strong evidence exists that α-
synuclein is involved in neurotransmitter re-uptake, as well as moving vesicles from 
the reserve pool to the readily-releasable pool (Lashuel et al., 2013). α-synuclein 
knockout (KO) mice show deficits in hippocampal signaling that corresponds to the 
inability to replenish the readily releasable pool of synaptic vesicles (Cabin et al., 
2002). Overexpression of α-synuclein results in reduced neurotransmitter release, 
and a decrease in readily releasable vesicles (Lashuel et al., 2013). α-synuclein KO 
mice are viable indicating that this protein is not essential for signaling but rather has 
a protective function, that becomes important under neural stress (Lashuel et al., 
2013). Looking at the structure unfortunately does not reveal much about the 
proteins function. 
α-synuclein is approximately 14.4 kDa and consists of, a lysine rich n-terminal that 
regulates interactions with the membrane, and an unstructured carboxyl tail that 
mediates protein and metal binding interactions (Lashuel et al., 2013). Amino acids 
65-90 are known as the non-amyloid-β component (NAC) of AD plaque. The NAC 
region is critical for oligomerization and fibril formation (Lashuel et al., 2013; Luk et 
al., 2009). Its ability to oligomerize is most likely proportional to the concentration of 
it. 
Concentration of α-synuclein depend on rate of synthesis as well as degradation. 
Imbalance in production of α-synuclein, as well as failure to degrade the protein at a 
normal rate, may lead to disease (Figure 1). Copy number variations resulting in 
higher levels of α-synuclein greatly increase the risk for PD. Most common mutations 
do not increase the concentration but increases α-synucleins propensity to 
oligomerize (Lashuel et al., 2013). Therefore, we need to consider not only the 
concentration but also the aggregation propensity. 
α-synuclein most likely exists as a stable monomer and it is not yet known whether 
oligomerization or fibrillization have a physiological effect. However, conservation of 
the NAC region suggests that the ability to aggregate has an unknown use. While, α-
synuclein is unstructured in solution, various factors have been shown to stabilize its 
structure as well as modulate its aggregation propensity. Proteolysis, post-
translational modifications, oxidative stress, phospholipids and metal ions modulate 
aggregation propensity (Lashuel et al., 2013). α-synuclein has been shown to take a 
variety of conformations including dimers, tetramers, oligomers, proto-fibrils and 
  
fibrils (Deleersnijder, Gerard, Debyser, & Baekelandt, 2013). The importance of 
these various α-synuclein species in health and disease are still under debate. 
Monomers can be considered non-toxic as they occur naturally within the body. 
Tetramers have recently been suggested to be the physiological conformation of α-
synuclein, and are  resistant to aggregation (Bartels, Choi, & Selkoe, 2011). 
Furthermore, mutations in α-synuclein have been shown to decrease tetramer 
levels, increasing aggregation propensity (Dettmer et al., 2015) .  However, there is 
still debate about the existence of tetramers as a large-scale verification study found 
that monomeric α-synuclein is the dominant conformation in the central nervous 
system, as well as various other α-synuclein sources. These experiments were 
conducted using a wide variety of techniques, and by seven independent research 
groups  (Fauvet et al., 2012).  
The nature of the toxic α-synuclein species is also contentious. Initially, the toxic 
species was thought to be the fibrillar aggregates found in Lewy neurites and Lewy 
bodies. However, the main toxic species is now thought to be oligomeric (Lashuel et 
al., 2013). Furthermore, it cannot be ruled out that even monomers may contribute to 
toxicity due to their unstructured nature. Monomers could activate any number of 
toxic downstream pathways in PD. The majority of in-vitro, in-vivo and post-mortem 
analysis assume oligomers or fibrils are toxic, finding a good correlation between 
aggregated oligomeric and fibrillar α-synuclein, and neurotoxicity. Deletions of α-
synuclein amino acids 71-82 abolishes its ability to aggregate and with it the typically 
observed neurotoxicity (Periquet, Fulga, Myllykangas, Schlossmacher, & Feany, 
2007). Therefore, the aggregation mechanics of α-synuclein are directly linked to the 
observed toxicity and PD progression.  
To summarize, the level of α-synuclein aggregates depend on both the 
concentration of monomers, the rate at which these monomers form aggregates and 
the rate at which these aggregates is cleared. Therefore, strategies that target α-
synuclein concentration and aggregation propensity present a good target for novel 
therapeutic approaches (Figure 1). 
  
  
Factor Evidence Therapeutic approaches Reference 
Rate of 
transcription 
Methylation of α-
synuclein is reduced 
in PD patient brains 
transcriptional activators / 
repressors, epigenetic 
modulation 
(Jowaed, 
Schmitt, 
Kaut, & 
Wüllner, 
2010) 
Stability of 
mRNA 
Reduced α-synuclein 
levels observed after 
siRNA treatment 
leading to improved 
disease condition 
siRNA, miRNA (Gorbatyuk 
et al., 2010; 
McCormack 
et al., 2010) 
Rate of 
translation 
no evidence no specific target 
opportunities 
  
Propensity to 
aggregate 
Δ71-82 deletion 
abolishes 
aggregation, 
pathogenic 
mutations increase 
aggregation 
propensity 
gene editing, stabilization of 
monomers 
(Deleersnijd
er et al., 
2013; 
Periquet et 
al., 2007) 
Degradation 
of monomers 
inhibition of 
proteasome leads to 
inclusion body 
formation in ventral 
mesencephalic 
cultures 
Targeting monomers to 
lysosome or proteasome 
(McNaught 
et al., 2002) 
Degradation 
of toxic 
aggregates 
Catecholamines can 
stabilize proto-fibrillar 
aggregates and 
increase toxicity, 
defects in protein 
degradation are 
seen frequently in 
PD patients 
decreasing aggregate 
stabilizers that may include 
catecholamines, targeting 
aggregates to lysosome or 
proteasome, immunotherapy 
targeting aggregates 
(Conway et 
al., 2001; 
Masliah et 
al., 2011) 
 
Figure 1. Factors affecting level of α-synuclein and potential treatment opportunities 
  
2.3.2 Mitochondrial recycling and oxidative stress 
Parkin is another gene important for PD was discovered just a year later. This gene 
segregated in an autosomal recessive fashion in a Japanese cohort (Kitada et al., 
1998). Parkin mutations result in juvenile onset PD, with symmetric onset of 
symptoms and slow progression. Parkin mutations were not associated with α-
synuclein positive Lewy bodies initially, but it is now accepted that some Lewy 
bodies may form in the substantia nigra and locus coeruleus (Pramstaller et al., 
2005). α-synuclein is also a substrate for parkin, and mutations in parkin result in 
aggregation of α-synuclein (Shimura et al., 2001). However homozygous loss of 
parkin function leads to pure nigral degeneration without Lewy body inclusions. 
Therefore, Parkin is able to cause PD independently of α-synuclein (Hardy, Lewis, 
Revesz, Lees, & Paisan-Ruiz, 2009). 
Parkin is also involved in the ubiquitin-proteasome system acting as an E3 ligase 
responsible for ubiquitinating proteins. Parkin is essential for mitochondrial quality 
control together with Pink-1. Pink-1 accumulates on the mitochondrial membrane. 
Through elegant experimentation in drosophila it was shown that Pink-1 is upstream 
of Parkin (Park et al., 2006). Post translational modification of Parkin such as 
phosphorylation by Pink-1 results in activation of Parkin leading to ubiquitination of 
various mitochondrial proteins and eventually autophagy of the mitochondrion 
(Durcan & Fon, 2015). Both mutations in Parkin and PINK-1 can lead to PD in an 
autosomal recessive manner.  It is unclear how damaged mitochondrial recycling 
results in PD.  
A widely accepted but not conclusively proven theory states, that nigral 
dopaminergic cells are very sensitive to oxidative stress (M. P. Murphy, 2009). This 
is due to the production of catecholamines already resulting in large quantities of 
reactive oxygen species (ROS). Mitochondria are another major source of ROS in 
the cell. Decreased functioning of complex I leading to a high protonmotive is one of 
the major drivers behind ROS production (M. P. Murphy, 2009). MPTP a known PD 
inducing neurotoxin blocks complex I. Inability to clear damaged mitochondria results 
in a marked increase of reactive oxygen species (ROS) and may cause the toxicity 
specifically affecting midbrain dopaminergic neurons. DJ-1 is another gene linked to 
PD and functions as a sensor for oxidative stress and protects neurons from the 
stress. Incorrect mitochondrial recycling leading to oxidative toxicity may therefore be 
one of the pathways leading to PD. 
  
John Hardy suggested that there are multiple pathways leading to PD, based on the 
known PD genes (Hardy et al., 2009). Mitochondrial dysregulation as well as 
aggregation of α-synuclein can lead to PD.  These pathways have complex 
interactions but are able to trigger PD independently (Hardy et al., 2009; Henchcliffe 
& Beal, 2008). In addition to these two well established canonical PD pathways there 
has been the proposition of a third pathway that induces PD by affecting lysosomal 
processing (Hardy et al., 2009). 
LRRK-2 is another gene which if mutated can cause PD and while penetrance of PD 
varies with mutation, the most common G2019S has nearly complete penetrance at 
the age of 80. Again, very little is known about why LRRK-2 causes PD. Lewy bodies 
are not present in all cases meaning that while this mutation seems to promote 
formation of Lewy bodies, it has secondary toxicity independent of α-synuclein 
aggregation (Hardy et al., 2009).  
Despite a variety of PD genes being identified and characterized we still know 
surprisingly little about the cause of the majority of PD cases. This is because most 
PD patients do not have a mutation in disease causing gene. PD is most likely 
polygenic and shows strong environmental influence, this makes the causes leading 
to PD extremely difficult to detect. 
2.3.3 Environmental causes of PD 
PD in most cases is sporadic meaning that the disease cause is not known or not 
determinable. Studies have mainly focused on genetic factors to help us understand 
molecular pathways that are obfuscated in sporadic disease. However, a few 
environmental factors have extremely clear link to being causative of PD. The 
earliest environmental link was found in a subset of patients suffering from the 
Spanish flu. These patients developed post-encephalitic Parkinsonism. This 
originally lead to the false conclusion that PD is entirely determined by environmental 
factors, but after the flu of 1918 no other influenza virus has been linked to causing 
PD (Poskanzer & Schwab, 1963). Another argument for the environmental 
hypothesis was the famous neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). The faulty synthesis of meperidine an opioid analgesic resulted in MPTP 
being a major impurity that a variety of people ended up self-injecting. People who 
injected this mixture rapidly presented with aggressive parkinsonian symptoms 
(Davis et al., 1979; Langston, Ballard, Tetrud, & Irwin, 1983). MPTP acts as a 
  
prodrug and is converted to MPP+ by monoamine oxidase B (MAO-B). MPP+ can 
then act as a complex I inhibitor in the mitochondria resulting in severe loss of 
dopaminergic neurons in the substantia nigra (Richardson et al., 2007). 
Rotenone is a commonly used insecticide and piscicide that works very similar to 
MPTP. Rotenone blocks electron transfer in complex I, resulting in ROS creation. 
While highly toxic to fish and insect’s, rotenone is only mildly toxic in humans and 
other mammals. At commonly used concentrations it is not taken up through the 
skin. However, exposure to rotenone even at very low concentration has been linked 
to increased risk of PD (Tanner et al., 2011). Paraquat a herbicide that works by 
creation of ROS has also been linked to PD (Tanner et al., 2011). Traumatic brain 
injuries have also been shown to have a small but significant effect in increasing the 
risk of developing PD (Gardner et al., 2015). It is not clear why sustaining brain injury 
would lead to PD, but it may be by potentially inducing oxidative stress in response 
to the injury. Studying both environmental and genetic pathways shows that there 
are clear overlapping molecular pathways. Especially oxidative stress and damage 
to mitochondria seem to cause PD.  
Another interesting environmental interaction is that of smoking which reduces the 
risk of PD. This link was noticed as early as 1959, when there was a large scale 
effort to link health concerns to smoking (Dorn, 1959). It is commonly believed to be 
the nicotine in cigarettes that reduces the risk of developing PD, but no nicotine 
receptor targeting therapeutics are currently licensed for PD. It has been suggested 
that decreased activity of MAO-B in smokers reduces the risk of PD as it can reduce 
the impact of environmental toxins, as well as decrease breakdown of dopamine to 
toxic intermediates (Fowler et al., 1998). However, the molecular pathway underlying 
protection from PD in smokers is still unclear. 
2.3.4 Parkinsonism plus syndrome 
Additionally, various diseases are now classified as Parkinson’s disease plus 
syndrome and fall into the category of synucleinopathies (dementia with Lewy bodies 
and multiple systems atrophy) or Tauopathies (Corticobasal degeneration, 
frontotemporal dementia and Parkinsonism linked to chromosome 17, Pick’s 
disease, progressive supra-nuclear palsy). Given that PD can have such varied 
etiology it is likely that the nigral dopaminergic neurons are especially susceptible to 
damage explaining why several independent pathways converge on a set of clinical 
  
symptoms defined as PD. PD is therefore not a single disease but rather appears to 
be an endpoint resulting from failure of a variety of different pathways. Great variety 
can be seen in the presentation of the disease which appears to be related to the 
heterogeneous molecular causes of the disease. By studying pathways that lead to 
PD we may gain a better understanding of how to treat it. Interestingly, patients with 
Gaucher’s disease and their relatives are particularly susceptible to PD. It is 
therefore warranted that the link between the two diseases is investigated in greater 
detail. 
2.4 GAUCHER’S DISEASE 
Gaucher’s disease (GD) is one of the 41 known lysosomal storage disorders (LSD). 
It was first described by Gaucher in 1882 (Kahn, 2007). This fairly rare disorder has 
an incidence of 1 in 100,00 of the general population, but is far more common in 
Ashkenazi Jews reaching a prevalence of 1 in 1,000 (Stirnemann & Belmatoug, 
2012). GD is autosomal recessive and characterized by deficiency in 
glucocerebrosidase activity. Glucocerebrosidase is a lysosomal enzyme that is 
responsible for cleaving the β-glucosidic linkage in glucosylceramide (Mehta, 2006). 
Decrease in glucocerebrosidase activity can result in three distinct forms of GD. The 
most common form is type 1, which is also described as non-neuronopathic. The 
most common symptoms are enlarged liver and spleen, anemia, thrombocytopenia 
and bone disease. Type II and type III GD are neuronopathic with variable 
pathology. Type II presents early in life and shows rapid progressive neurological 
deterioration, leading to death. Type III GD also presents variable pathology but can 
include myoclonic epilepsy, horizontal saccadic eye movements and hydrocephalus. 
All types of GD are caused by mutations in the GBA 1 gene (Ellen Sidransky & 
Lopez, 2012). Two therapies are currently used to treat GD. Enzyme replacement 
therapy relies on injections of recombinant GCase and is an effective treatment for 
type I GD. Substrate reduction therapy is based on applying a glucosylceramide 
synthase inhibitor, which reduces the amount of glucosylceramide produced, and is 
used for mild forms of GD. Treatment of the neurological symptoms however has 
always been poor, as the recombinant enzyme does not pass through the blood 
brain barrier. 
  
2.5 THE LINK BETWEEN GAUCHER’S DISEASE AND PARKINSON’S 
DISEASE 
GBA 1 mutations were only identified as a risk factor for PD thanks to astute clinical 
observation. Epidemiologic analysis, linkage studies and genome wide analysis all 
failed to pick up the correlation (Rogaeva & Hardy, 2008). Early evidence came from 
a study in which six patients with GD type 1 developed PD (Neudorfer et al., 1996).  
It was later confirmed that patients and relatives of patients with Gaucher’s disease 
developed PD at a significantly higher rate (O Goker-Alpan et al., 2004). This 
sparked interest in finding out whether these two diseases were related. Large multi-
center trials were carried out and the rate of GBA1 mutations was a striking 18% in 
PD patients, compared to 4% in age matched controls (Gan-Or et al., 2008). This 
finding was replicated in other patient cohorts such as British patients, where GBA1 
mutations were found in 4.2% of PD patients versus 1.17% of control (Neumann et 
al., 2009). Similar results were obtained from a European screening study of 1130 
PD patients of which 6.7% had GBA1 mutations versus 1.0% in 391 controls 
(Lesage et al., 2011). Even by conservative estimates GBA1 is the most common 
genetic risk factor for PD. Most physicians interpret GBA1 mutations to be autosomal 
dominant with reduced penetrance. However, the penetrance of GBA1 mutations is 
most likely multigenic, making genetic counseling difficult without knowing more 
about the molecular pathways resulting in penetrance (Ellen Sidransky & Lopez, 
2012).   
A prospective study in Ashkenazi Jews found that carrying mutated alleles of GBA1 
decreased the age at which you develop PD. Homozygotes developed PD at a 
younger age (54.2 years) versus heterozygotes (65.2 years) and non-carriers (70.2). 
Furthermore, a significantly larger percentage of subjects developed PD if they were 
homo/heterozygotic for GBA1 (Alcalay et al., 2014; Bultron et al., 2010; Nalls et al., 
2013; E Sidransky et al., 2009). It was therefore clear that GBA1 was a strong risk 
factor for PD. While the association between GBA1 mutations and PD has been 
clearly demonstrated, the molecular mechanisms is still unknown. Both toxic gain of 
function and loss of function were proposed as potential explanations (Ellen 
Sidransky & Lopez, 2012). Mutated GCase could promote α-synuclein aggregation 
or be toxic to nigrostriatal dopamine neurons. Alternatively, loss of GCase function 
could promote substrate accumulation which may be toxic or loss of function results 
in reduced α-synuclein clearance. 
  
Initial observations supported the gain of function hypothesis. GBA1 heterozygotes 
with one non-functioning allele still develop PD at a much higher rate than normal. 
However, GBA1 does not demonstrate haploinsufficiency and patients with one 
mutated allele have nearly normal GCase functioning (Alcalay et al., 2014; Bultron et 
al., 2010; Nalls et al., 2013; E Sidransky et al., 2009).  Furthermore, the E326K 
GBA1 mutation does not cause a large reduction in GCase function. Homozygotic 
carriers of this mutation had GCase function at the lower end of the normal spectrum 
and did not have GD. Despite having little impact on GCase activity the E326K 
mutation increased the risk of developing PD (Duran et al., 2013).  
Furthermore, misfolded GCase is found in Lewy bodies suggesting that it may 
potentially aid α-synuclein oligomerization. It has been suggested that GCase and α-
synuclein interact in the lysosome (Yap et al., 2011). Lastly most GD patients do not 
develop PD indicating that it is not the absence of function that leads to development 
of the disease (Mazzulli et al., 2011). Therefore, a large body of evidence indicates 
that GBA1 mutations cause a toxic gain of function. 
However, loss of GCase function may also contribute to PD. GBA1 KO mice have 
increased levels of α-synuclein and a single injection of CBE raised the Striato-nigral 
levels of α-synuclein. Furthermore, decrease in GCase function may put stress onto 
the mitochondria leading to reactive oxygen species production, a process indicated 
in PD(Manning-Boğ, Schüle, & Langston, 2009; Osellame et al., 2013).  
Additional evidence for loss of function come from molecular studies. It has become 
clear that a decrease in GCase activity leads to increased α-synuclein both in vitro 
and in vivo (Manning-Boğ et al., 2009; Mazzulli et al., 2011). Increased levels of α-
synuclein increase the likelihood and speed at which α-synuclein oligomers form. PD 
patient brain analysis shows that even in sporadic PD patients there is a decrease in 
both the level of GCase protein and its activity level (K. E. Murphy et al., 2014). 
Therefore, both gain of function and loss of function seem important. 
2.6 THE RELATIONSHIP BETWEEN GCASE AND Α-SYNUCLEIN 
Both gain of function and loss of function theories seem to implicate α-synuclein as 
the link between GBA1 mutations and PD. A variety of crucial questions still remain 
unanswered. Does α-synuclein cause a decrease in GCase protein level and 
activity? Does decreased GCase activity increase levels of α-synuclein? Does one 
cause precede the other? 
  
Let us first look at the question of timing. In patients with homozygous or 
heterozygous GBA1 mutations it is obviously a decrease in GCase activity that 
precedes increased levels of α-synuclein. Conversely, in PD patients that have a 
SNCA triplication, the increased level of α-synuclein precedes decreased GCase 
activity. If we look at sporadic cases of PD there is no clear answer but interestingly 
PD patients with no mutations in GBA1 still show reduced GCase activity (K. E. 
Murphy et al., 2014). One of the most popular current theories is that there is no 
clear cause and effect but rather a cycle. 
The theory proposes a bi-directional feedback loop between GCase activity and level 
of α-synuclein (Mazzulli et al., 2011). Decrease in GCase activity leads to an 
increase in glucosylceramide which may stabilize small soluble α-synuclein 
oligomers. These oligomers then further impede the trafficking of GCase from the 
endoplasmic reticulum to the Golgi. This leads to depletion of lysosomal GCase and 
eventual dysfunction of the lysosome in general. This increases α-synuclein levels, 
due to a decrease in α-synuclein degradation in the lysosome (K. E. Murphy et al., 
2014; Sevlever, Jiang, & Yen, 2008; Vogiatzi, Xilouri, Vekrellis, & Stefanis, 2008). It 
therefore seems likely that both an increased level of α-synuclein and a decreased 
GCase activity can start a cycle resulting in the final observed pathogenic levels of α-
synuclein. Disrupting this cycle by increasing the functionality of GCase may be a 
viable way to interfere with PD pathogenesis or impede progression of PD. 
This feedback theory is supported by a study using cells that both overexpress α-
synuclein and are GBA1 -/-. In these cells there is profound lysosomal dysfunction is 
mimicked and there is an accumulation of insoluble α-synuclein oligomers. These 
data indicate that loss of GBA1 contributes to developing PD (Bae et al., 2015). 
However, other studies indicate that there is no correlation between GCase activity 
and α-synuclein levels (Cullen et al., 2011; Dermentzaki, Dimitriou, Xilouri, 
Michelakakis, & Stefanis, 2013).  In these papers, relationship of α-synuclein and 
GCase is assessed by inhibiting GCase with the specific inhibitor conduritol-β-
epoxide (CBE), rather than using genetic knock-out or knock-down strategies. After 
CBE treatment, which reduced GCase activity 95%, there was no significant 
increase in α-synuclein. However transfecting cells with AAVs expressing mutant 
isoforms of GCase results in marked increase of α-synuclein supporting the idea that 
there is a toxic gain of function mutation responsible for predisposing to PD rather 
than a loss of function. 
  
The idea of a toxic gain of function is also better supported by clinical evidence, as 
patients with GCase mutations have an increased incorporation of mutant GCase 
into Lewy bodies with about 90% of Lewy bodies being GCase positive in mutant 
carriers compared to 10% in age-matched controls (Ellen Sidransky & Lopez, 2012). 
GCase mutations are also present in diffuse Lewy body dementia  but not in multiple 
system atrophy (Ellen Sidransky & Lopez, 2012). This indicates that GCase and α-
synuclein interact directly in some way. In-vitro studies do show that GCase and α-
synuclein can interact on artificial lipid membranes (Yap, Gruschus, Velayati, 
Sidransky, & Lee, 2013; Yap et al., 2011). Therefore, it is still plausible that 
interactions between lipids, mutated GCase and α-synuclein is the cause for 
increased risk of developing PD. 
To summarize, the molecular mechanism by which GBA1 mutations act is still 
unknown. Many studies show that decrease in GCase activity increases levels of α-
synuclein and that α-synuclein can in turn reduce GCase activity (Manning-Boğ et 
al., 2009; Mazzulli et al., 2011; Yap et al., 2013, 2011). However, opposing studies 
did not find a correlation between GCase activity and α-synuclein. Instead they 
implicate misfolding of GCase as the primary cause showing that a variety of 
misfolded mutants are responsible for increased levels of α-synuclein (Cullen et al., 
2011; Dermentzaki et al., 2013). However, most studies agree that the mutations 
have an effect on α-synuclein levels, which increases likelihood of α-synuclein 
aggregation.  
3 GBA RNAI BUT NOT CATALYTIC INHIBITION OF 
GLUCOCEREBROSIDASE WITH CONDURITOL-β-
EPOXIDE INCREASES LEVELS OF TOTAL α-
SYNUCLEIN IN SH-SY5Y CELLS 
3.1 BACKGROUND FOR STUDY 1 
There is copious evidence that PD and GD are linked (Ellen Sidransky & Lopez, 
2012). The results of all currently published studies have been compiled in figure 2. 
However, the underlying molecular mechanism is still under debate. 
one of the first molecular links showed that administration of the GCase inhibitor 
conduritol-β-epoxide (CBE) led to an increase in levels of α-synuclein (Manning-Boğ 
et al., 2009). The results of this study showed a clear elevation of α-synuclein in SH-
SY5Ycells after treatment with 50 μM of CBE. However, escalating the dose to 100 
  
or 200 μM showed a lower level of α-synuclein despite increased GCase inhibition. 
Furthermore, a thorough replication study of these original experiments was unable 
to confirm an increase in α-synuclein (Dermentzaki et al., 2013). Another study found 
that mutant GBA1 forms can increase levels of α-synuclein. Administration of CBE 
did not lead to an increase in α-synuclein but overexpression of wildtype GCase 
decreased levels of α-synuclein (Cullen et al., 2011). However, Knockdown of 
GCase reliably increases levels of α-synuclein (Mazzulli et al., 2011; Schöndorf et 
al., 2014). One plausible mechanism by which alterations in GCase activity could 
affect α-synuclein is through increase in GCase substrate. 
Loss of GCase function leads to an increase in glucosylceramide and 
glucosylsphingosine (Dekker et al., 2011; Hamler et al., 2017). Incubation of α-
synuclein with these two lipids increased β-sheet confirmation (Taguchi et al., 2017). 
Furthermore, α-synuclein could be turned into pre-formed fibrils by incubation with 
glucosylceramide and glucosylsphingosine but not other common lipids. When lipid 
formed α-synuclein fibrils were added to cells, there was clear aggregation of α-
synuclein inside those cells (Taguchi et al., 2017). Therefore, loss of GCase function 
results in increased levels of glucosylceramide and glucosylsphingosine leading to α-
synuclein oligomerization. 
However, the loss of function hypothesis ignores some critical evidence. Mutant 
GCase is often found in Lewy bodies but normal GCase is not (Ozlem Goker-Alpan, 
Stubblefield, Giasson, & Sidransky, 2010). Furthermore, Cullen and colleagues 
transfected various cell lines with either mutant or wild-type GCase plasmids. Over-
expression of mutated GCase alongside WT GCase led to a significant increase in 
levels of α-synuclein independent of GCase activity (Cullen et al., 2011). 
Additionally, mutant GCase can be retained in the endoplasmic reticulum triggering 
the unfolded protein response and stressing the cell, possibly causing the cell death 
(Ron & Horowitz, 2005). Furthermore, patients with mutations that have little effect 
on GCase activity and heterozygous mutants still show an increased risk for PD 
even though they are sub-clinical for GD (Ellen Sidransky & Lopez, 2012). 
It is therefore, not clear yet whether a decrease in GCase activity, a decrease in 
GCase protein level or an increase in toxic mutant GCase function is the cause of 
increased α-synuclein and therefore the increased PD risk. We aimed to disentangle 
the complex cause of increased α-synuclein by directly comparing genetic knock-
down strategies and chemical inhibition strategies. We could show that RNA 
  
interference, but not chemical inhibition leads to an increase in α-synuclein. We 
suggest that chemical inhibition and genetic ablation strategies produce two distinct 
effects. Our results suggest caution in choosing which cellular GBA1 model is used 
to best mimic PD with GBA1 mutations. Based on the existing literature and our 
results we hypothesize that reduction in GCase levels decreases α-synuclein 
degradation via a direct interaction. (Aflaki, Westbroek, & Sidransky, 2017). This 
direct interaction would explain why mutated GCase accumulates with α-synuclein in 
Lewy bodies. Our data shows an increase in α-synuclein levels only when using 
RNAi and not by chemical inhibition. This hypothesis is consistent with the variety of 
different results observed (Figure 2). 
  
  
Chemical inhibition of Glucocerebrosidase Genetic Manipulation of GBA 1 
Treatment of differentiated SH-SY5Y cells with 
50-200 μM CBE for 48 hours increased levels 
of α-synuclein. Animals treated with CBE 
showed increased α-synuclein 
immunofluorescence (Manning-Boğ et al., 
2009). 
Lentiviral shRNA targeting GBA 1 resulted in 
50% Glucocerebrosidase KD and a 60% 
increase of α-synuclein (Mazzulli et al., 2011) 
Treatment of differentiated SH-SY5Ycells and 
rat primary cortical neurons with 50-200 μM 
CBE from one day to one week has no effect 
on α-synuclein (Dermentzaki et al., 2013). 
IPSC derived from GBA 1 mutation carriers 
(RecNil, L444P, N370S). Even RecNil iPSC 
had higher levels of α-synuclein (Schöndorf et 
al., 2014) 
Treatment of SH-SY5Ywith 50 μM CBE for 
one month showed a significant increase in α-
synuclein. Knockdown of GBA1 with siRNA 
did not yield significant increase in α-
synuclein.(Cleeter et al., 2013).  
Treating iPSC that have GBA1 mutations with 
small-molecule chaperone restores lysosomal 
glucocerebrosidase localization and activity 
and reduces α-synuclein levels to that 
comparable of controls. (Mazzulli et al., 2016) 
Treatment with CBE (10 - 100 μM) had no 
effect on α-synuclein levels in MES-SNCA 
cells. Overexpression of glucocerebrosidase 
mutants especially D409V caused remarkable 
increase in α-synuclein levels and this 
increase was unrelated to GCase activity. 
(Cullen et al., 2011). 
Overexpression of mutated 
glucocerebrosidase (D409H, L444P, N370S, 
E235A, E340A) but not WT GBA 1 led to a 
great increase in α-synuclein levels. (Cullen et 
al., 2011) 
Treatment with 25 μM CBE for 48 hours 
caused visual increase in α-synuclein 
immunolabeling in differentiated control iPSC 
(Schöndorf et al., 2014). 
Knockout of GBA 1 in SH-SY5Ycells results in 
double the level of α-synuclein. (Bae et al., 
2015) 
Treatment of primary cultures with 10 μM CBE 
replacing media every 3 days for 10 days. 
There was approximately 50% increase in WB 
and a 10% increase using ELISA to quantify 
α-synuclein (Magalhaes et al., 2016). 
 
Treatment of iPSC with 50µM CBE for 7 days 
did not increase levels of soluble α-synuclein 
but did increase levels of insoluble α-
synuclein. (Zunke et al., 2018) 
 
Figure 2. Overview of cellular experiments manipulating GCase activity and 
measuring α-synuclein. 
  
  
4 SUMMARY PAPER I 
GBA RNAi but not catalytic inhibition of glucocerebrosidase with Conduritol-β-
epoxide increases levels of total α-synuclein in SH-SY5Y cells 
4.1 ARTICLE SUMMARY 
Our aim was to investigate the correlation between α-synuclein and GCase activity in 
greater detail. We focused on this specific problem because of conflicting reports in 
the literature and our own experimental data (Dermentzaki et al., 2013; Mazzulli et 
al., 2011). We used four different cell models: 1) undifferentiated SH-SY5Y cells, 2) 
differentiated SH-SY5Y cells, 3) N2a cells over-expressing α-synuclein, 4) rat 
midbrain primary cultures. 
Our primary goal was to confirm or refute that CBE increases levels of α-synuclein. 
First, we investigated the effect of CBE treatment in primary cultures and 
differentiated SH-SY5Y cells over a 10 day timespan. CBE treatment reduced 
GCase activity by over 95%, however we did not see any significant increase in α-
synuclein (Art 1, Figure 1). We could show that even when treated over a long-time 
span of 30 days, there is no noticeable increase in soluble α-synuclein as measured 
by western blot (Paper 1, Figure 2). This confirmed the data published by 
Dermentzaki and colleagues (Dermentzaki et al., 2013). 
We then decided to go ahead and still attempt a genetic manipulation of GCase 
levels by use of siRNAs. Our theory was that while inhibition of GCase with CBE 
does not increase levels of α-synuclein, genetic manipulation of GBA1 does increase 
α-synuclein. This was based on multiple publications showing a significant increase 
in α-synuclein after genetic manipulation (Figure 2). We could confirm that treatment 
for 10 days with GBA1 siRNA significantly increased levels of α-synuclein. We 
carefully controlled this experiment by also using GBA2 siRNA and CBE. We 
therefore show that knockdown of GCase but not chemical inhibition, causes the 
increase in α-synuclein. 
This result led us to speculate that GCase influenced α-synuclein in an activity 
independent way. We based this on in-vitro studies, that demonstrated α-synuclein 
binding to and inhibiting GCase (Yap et al., 2013). We therefore designed an 
experiment in which we would add recombinant GCase to our cell model. We again 
demonstrated that siRNA treatment but not addition of CBE increased α-synuclein. 
  
Furthermore, we show that dual addition of CBE and GBA1 siRNA do not have a 
greater effect than just adding the siRNA. We could also show that addition of 
recombinant GCase restores GCase activity and reduces α-synuclein. However, we 
were not able to confirm that this is done by an activity independent mechanism. 
Treatment of differentiated SH-SY5Y cells with GBA1 siRNA followed by addition of 
recombinant GCase that is preincubated with CBE, did not restore physiological 
levels of α-synuclein (Paper 1, Figure 4). 
In conclusion, using careful controls, we could show that knockdown of GCase 
increases levels of α-synuclein, while chemical inhibition with CBE, did not increase 
levels of α-synuclein. This fact is of major importance to the literature as it explains 
the variety of results that were obtained by different experimental approaches (figure 
2). This distinction is a subtle one but has important physiological implications for 
potential therapeutic applications. When designing new treatments, priority should 
be given to approaches that stabilize GCase rather than focus solely on the increase 
in GCase activity. It also suggests that treatments aimed at increasing levels of 
GCase in PD related areas may be a viable strategy to reduce levels of α-synuclein. 
Already a variety of potential treatments are adopting this strategy by using small 
molecular chaperones such as Ambroxol (Sanchez-Martinez et al., 2016). 
 
  
  
 
5 SAPOSIN C REDUCES LEVELS OF Α-SYNUCLEIN AND 
DISLODGES IT FROM GLUCOSYLCERAMIDE-
ENRICHED LIPID MEMBRANES  
5.1 BACKGROUND TO STUDY 2 
Various studies have shown that restoring normal GCase functioning in cells with 
GBA1 mutations results in a decrease in levels of α-synuclein (figure 2). iPSC's 
obtained from patients with GBA1 mutations have higher levels of α-synuclein than 
control. Using Zinc-finger nucleases to insert a non-mutated GBA1 alleles results in 
a decrease in levels of α-synuclein (Schöndorf et al., 2014). Overexpression of WT 
GCase in HEK293-SNCA cells led to a significant decrease in α-synuclein (Cullen et 
al., 2011). Use of a small molecular chaperone to aid folding and processing of 
mutant GCase through the endoplasmic reticulum into the lysosome was able to 
revert the increase in α-synuclein observed in cell lines with GBA1 mutations 
(Mazzulli et al., 2016; Sanchez-Martinez et al., 2016). This led us to hypothesize that 
activating GCase could be used as a potential treatment for PD. We decided to use 
saposin C, an endogenous activator of GCase, to investigate potential beneficial 
effects of saposin C in PD. 
Prosaposin is the propeptide of saposin C and is cleaved into saposin A-D. 
Saposin's A-D all assist in lysosomal degradation of lipids by acting as sphingolipid 
activator proteins (Kishimoto, Hiraiwa, & O’Brien, 1992; Solly Weiler, Tomich, 
Kishimoto, O’Brien, & Barranger, 1995). Saposin C assists GCase by modifying the 
lipid membrane in a detergent like manner and exposing the headgroup of the lipids 
(Lieberman, 2011).  
There are many reasons why saposin C could be beneficial in PD.(i) Saposin C can 
increase GCase activity by acting as a chaperone, preventing degradation of GCase 
and extending its half-life (Sun, Qi, & Grabowski, 2003). (ii) Saposin C contains a 
neurotrophic sequence close to its n-terminal (O’Brien, Carson, Seo, Hiraiwa, & 
Kishimoto, 1994; O’Brien et al., 1995). (iii) Saposin C is a potential ligand for the 
GPR37 orphan receptor (Meyer, Giddens, Coleman, & Hall, 2014). GPR37 is found 
in Lewy bodies and may provide a druggable target for treatment of PD, because it 
can interact with the D2 receptor and DAT, to alter dopaminergic signaling. (iv) GPR 
37 can be neuroprotective when activated. (v) GPR37 forms part of the core 
  
structure in idiopathic PD Lewy bodies. (Leinartaité & Svenningsson, 2017). (vi) 
Furthermore, ex-vivo experiments show that α-synuclein can inhibit GCase activity at 
lysosomal pH. This inhibition is reversed by addition of Saposin C (Yap et al., 2013). 
Therefore, Saposin C is an interesting peptide that interacts with multiple PD 
pathways. To investigate whether saposin C had neuroprotective properties in PD, 
we generated short saposin C peptides. We could confirm that saposin C activates 
GCase and that this depends on amino acids 41-68 (S Weiler, Kishimoto, O’Brien, 
Barranger, & Tomich, 1995). However, attempting to attach a cell penetrating motive 
and applying the peptide to SH-SY5Ycells was not sufficient to increase GCase 
activity. Instead we created a stable cell line overexpressing prosaposin under the 
CMV promoter. This leads to a significant increase in GCase activity and a 
subsequent decrease in α-synuclein. The decrease in α-synuclein persisted even 
after inhibition of GCase with CBE indicating another mechanism of action. We 
showed that saposin C can effectively detach α-synuclein from artificial membranes, 
which are a primary site of α-synuclein aggregation (Kalia & Lang, 2015). Our data 
indicates that saposin C is important in PD and may be a potential treatment target. 
  
  
6 SUMMARY PAPER II 
Saposin C reduces levels of α-synuclein and dislodges it from 
glucosylceramide-enriched lipid membranes  
6.1 ARTICLE SUMMARY 
In paper II we investigate saposin C as a potential treatment for PD. Our initial idea 
was to produce small peptide analogues of saposin C, containing the activating 
sequence for GCase. We thought that these small peptides could increase GCase 
activity and therefore be protective in PD. We designed a variety of sequences and 
were able to confirm that amino acids 41-68 of the saposin C peptide activate 
GCase (S Weiler et al., 1995). We attached a cell penetrating peptide sequence to 
the activating region of saposin C (Lindgren, Hällbrink, Prochiantz, & Langel, 2000). 
However, we quickly noticed that while activating GCase in extracted lysosomes was 
easy, getting the peptide into the cell in sufficient quantities was very difficult. We 
decided that changing our approach and using an overexpressing cell line would be 
more feasible for our studies. 
We designed a vector containing prosaposin, the propeptide of saposin C. It 
expresses prosaposin linked to GFP under a CMV promoter. We showed that 
PSAP-GFP was successfully expressed in our cell line by western blot. We also 
confirmed that PSAP is trafficked to the lysosome as there was correlation of GFP 
fluorescence and lysotracker deep red, a chemical dye that stains lysosomes. We 
could also show that there is an increase in GCase activity and a decrease in levels 
of α-synuclein (Paper 2, figure 2). 
This result was very interesting, and we wanted to investigate it further. We used 
siRNA targeting prosaposin to evaluate whether knockdown of prosaposin causes 
increase in α-synuclein levels. We treated cells over a period of 10 days and found 
that reducing prosaposin levels has the inverse effect of prosaposin overexpression. 
We saw a significant increase in α-synuclein (Paper 2, figure 3). However, 
knockdown of prosaposin was also slightly toxic to the cells as it is an important 
lysosomal protein. The increase in α-synuclein may therefore be a general sign of 
lysosomal dysfunction (Ebrahimi-Fakhari, Wahlster, & McLean, 2012). Nonetheless, 
we provide further evidence that prosaposin influences α-synuclein metabolism and 
is therefore an interesting target in PD. 
  
It was at this time point, that our data from paper 1 indicated that GCase activity was 
not related to levels of α-synuclein. We therefore, confirmed that this was also the 
case in our PSAP-GFP cell line. We could show that inhibition of GCase with CBE in 
our PSAP overexpressing cell line did not alter levels of α-synuclein. Prosaposin 
overexpressing cells still had significantly lower levels of α-synuclein, compared to 
controls. 
At this point we began looking for alternative theories to explain the phenomena. 
One hypothesis we developed is that α-synuclein binds to lipid membranes and that 
the saposins can dislodge α-synuclein from these membranes making it more 
accessible to degradation. This was based on data that α-synuclein interacts with 
lipids and that lipid rafts may act as a source of α-synuclein aggregation (Alattia, 
Shaw, Yip, & Prive, 2007; Simons & Gruenberg, 2000; Taguchi et al., 2017). To 
investigate this hypothesis, we generated recombinant lipid vesicles using 
phosphocholine and glucosylceramide. We also generated recombinant α-synuclein 
and saposin C. 
The artificial vesicles were incubated with α-synuclein. The vesicles were then 
loaded into a spin filter that would retain the vesicles and bound α-synuclein. We 
confirmed that α-synuclein readily binds to lipid vesicles. We then added either 
recombinant saposin C or control peptide to the spin filter. We show that especially 
saposin C can dislodge α-synuclein from lipid membranes (Article 2, figure 4). 
We conclude that saposin C presents an interesting target for PD. It reduces α-
synuclein levels and increases GCase activity. Additionally, it helps dislodge α-
synuclein from lipid membranes, making it potentially more accessible for 
degradation and preventing aggregates from forming. 
  
  
7 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
Our overarching question for this thesis was whether modulation of GCase is a 
potential treatment for PD? 
In study I, we show that using RNAi to decrease levels of GCase leads to an 
increase in levels of α-synuclein. Using CBE on the other hand does not change 
levels of α-synuclein. Our study is supported by a recent publication showing that 
administration of CBE can cause aggregation of α-synuclein without changing the 
soluble levels (Zunke et al., 2018). We therefore gain valuable mechanistic insight 
into how GBA1 mutations predispose to PD. Our data suggests that increasing the 
amount of GCase trafficked to the lysosome is protective in PD.  
Our data supports a variety of treatments such as administration of GCase in the 
central nervous system. Rocha and colleagues showed that viral injection causing 
GCase overexpression in rats was protective in PD models (Rocha et al., 2015). Our 
results especially support the use of GCase chaperones in PD patients with GBA1 
mutations. This is supported by recent animal data showing that ambroxol a 
molecular chaperone of GCase is protective against 6-Hydroxydopamine treatment 
in rats (Mishra, Chandravanshi, Trigun, & Krishnamurthy, 2018). Additionally, more 
and more molecular chaperones are becoming available for GCase. Ambroxol has 
already shown great promise as a potential treatment for PD (Bouscary et al., 2019; 
Sanchez-Martinez et al., 2016; Yang, Beavan, Chau, Taanman, & Schapira, 2017). 
Recently, a group demonstrated a slow release system for ambroxol (Enshaei et al., 
2019). Another, interesting recent finding is that Arimoclomol, a heat shock protein 
amplifier has been shown to increase levels of GCase and GCase activity in GD 
models (Fog et al., 2018). Therefore, our first study supports the claim that GCase 
modulation can be a useful treatment for PD and indicates that chaperone therapy 
enabling correct folding and trafficking of GCase is a promising approach. 
In Study II we present evidence that the endogenous GCase activating protein 
saposin C, has the ability to increase GCase activity and protein levels. Saposin C 
therefore not only acts as a co-factor for GCase but may also act as a molecular 
chaperone preventing GCase degradation. Overexpressing prosaposin leads to a 
decrease in α-synuclein. Therefore, increasing PSAP expression is most likely 
protective in PD for a variety of reasons. I) it increases GCase activity, II) it increases 
  
the protein level of GCase. III) Saposin C can detach α-synuclein from biological 
membranes containing glucosylceramide. IV) Saposin C contains a neurotrophic and 
neuroprotective fragment that may be beneficial in PD. V) Saposin C is a suggested 
ligand for GPR37 and GPR37L1 receptors and activation of these receptors may be 
beneficial in PD (Meyer et al., 2014). Again, our data supports the claim that GCase 
modulation may be protective in PD. 
One finding that was particularly surprising is that saposin C can detach α-synuclein 
from artificial glucosylceramide vesicles. Additionally, it can break interaction 
between GCase and α-synuclein (Yap et al., 2013, 2015). So while Saposin C may 
act directly on GCase to produce a protective effect, it also acts directly on α-
synuclein.  
To conclude we present data suggesting that GCase levels rather than GCase 
activity are important for preventing PD. Furthermore, we investigated saposin C and 
highlight its potential as a target in PD. We hope that this work can contribute to the 
ever-growing literature on PD, and that work on saposin C as a potential clinically 
relevant protein for PD can continue. 
While we have provided some promising data. Much work remains to be done. The 
exact effect of saposin C in PD needs to be characterized with great care. The main 
aim of future studies should be to prove a protective effect of saposin C 
overexpression in clinically relevant models such as dopaminergic neurons 
differentiated from iPSC’s of patients with GD and PD. Exploring the effect of 
saposin C overexpression in animal PD models using viral constructs is also 
desirable. A particularly relevant models would be that of Luk and co-workers. 
Aggregation of α-synuclein seems to be a primary mechanism for developing PD. 
Injecting mice with pre-formed fibrillar α-synuclein can induce a pathology strikingly 
similar to PD (Luk et al., 2012). A decrease in α-synuclein due to PSAP 
overexpression logically dictates a decrease in aggregation speed of α-synuclein. 
We therefore hypothesize that over-expression of PSAP in this mouse model should 
have a protective effect. 
Furthermore, we need to unambiguously show that it is saposin C, and not other 
saposins, or full length prosaposin, which are responsible for the decrease in α-
synuclein. As saposin C is cleaved from a precursor peptide in the lysosome, it is 
  
difficult to pinpoint a specific effect to saposin C and exclude the action of the other 
saposins. 
Finally, we would like to investigate approaches that could be used to increase 
prosaposin, and therefore saposin C levels in PD patients. Prosaposin is trafficked to 
the lysosome by interaction of its c-terminal region with the sortillin receptor (Carvelli, 
Libin, & Morales, 2015). However, prosaposin can also be secreted into the 
extracellular space. It is known that the 65 kDa form of prosaposin is secreted, while 
the 68-70kDA PSAP is targeted to the lysosome. The mechanism gating this 
trafficking is unknown (Carvelli et al., 2015). Knowing more about the trafficking of 
PSAP may aid in developing strategies that increase intralysosomal saposin C 
levels. Finally, our original idea was to generate small synthetic peptides that could 
be used for treatment of PD. However, due to the complexity of the targeting 
involved we were unable to do so. Therefore, the biology of prosaposin is still not 
understood well enough to effectively use this protein as a potential treatment. We 
hope by showing that it has a possible protective effects in PD, we will encourage 
research to further explore this promising pathway. 
Finally, we wish to remark that PD is a devastating neurodegenerative disorder. 
Patients afflicted with this disease gradually lose the ability to perform voluntary 
movement. Therefore, these patients often lose their independence and the ability to 
continue living a normal life in the home they have known for decades. Many PD 
patients also face cognitive decline, and depression is one of the most frequent co-
morbidities in PD. As scientists we must not forget our humanity and let it guide our 
efforts. Hopefully, with the combined skill and patience of thousands of dedicated 
researchers, we are inching closer towards the truth, allowing us to prevent or at 
least slow this devastating disease. 
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